Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial

PURPOSE: To evaluate the safety and efficacy of a preservative-free latanoprost 0.005% formulation (T2345) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) compared to benzalkonium chloride–preserved latanoprost 0.005% (BPL) formulation in the United States (US). PATI...

Descripción completa

Detalles Bibliográficos
Autores principales: Bacharach, Jason, Ahmed, Iqbal Ike K, Sharpe, Elizabeth D, Korenfeld, Michael S, Zhang, Steven, Baudouin, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478989/
https://www.ncbi.nlm.nih.gov/pubmed/37674591
http://dx.doi.org/10.2147/OPTH.S414015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478989/
https://www.ncbi.nlm.nih.gov/pubmed/37674591
http://dx.doi.org/10.2147/OPTH.S414015

Ejemplares similares